Ligand Pharmaceuticals Coverage Initiated by Analysts at Roth Capital (LGND)
Separately, analysts at Ned Davis Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $68.64.
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) traded up 3.70% on Wednesday, hitting $62.91. 260,033 shares of the company’s stock traded hands. Ligand Pharmaceuticals has a 52-week low of $35.21 and a 52-week high of $80.42. The stock has a 50-day moving average of $65.49 and a 200-day moving average of $64.47. The company has a market cap of $1.304 billion and a price-to-earnings ratio of 104.06.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings data on Wednesday, May 7th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.10. The company had revenue of $16.00 million for the quarter, compared to the consensus estimate of $13.63 million. The company’s revenue for the quarter was up 36.8% on a year-over-year basis. On average, analysts predict that Ligand Pharmaceuticals will post $1.44 earnings per share for the current fiscal year.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.